RT Journal Article
SR Electronic
T1 Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.19.20215368
DO 10.1101/2020.10.19.20215368
A1 Kathy Kamath
A1 Elisabeth Baum-Jones
A1 Gregory Jordan
A1 Winston Haynes
A1 Rebecca Waitz
A1 John Shon
A1 Steve Kujawa
A1 Lyn Fitzgibbons
A1 Debra Kessler
A1 Larry Luchsinger
A1 Yale IMPACT Team
A1 Patrick Daugherty
YR 2020
UL http://medrxiv.org/content/early/2020/10/21/2020.10.19.20215368.abstract
AB Despite the high level of morbidity and mortality worldwide, there is increasing evidence for asymptomatic carriers of the novel coronavirus SARS-CoV-2. We analyzed blood specimens from 1,559 healthy blood donors, collected in the greater New York metropolitan area between the months of March and July 2020 for antibodies to SARS-CoV-2 virus. Using our proprietary technology, SERA (Serum Epitope Repertoire Analysis), we observed a significant increase in SARS-CoV-2 seropositivity rates over the four-month period, from 0% [95% CI: 0 - 1.5%] (March) to 11.6% [6.0 - 21.2%] (July). Follow-up ELISA tests using S1 and nucleocapsid viral proteins confirmed most of these results. Our findings are consistent with seroprevalence studies within the region and with reports that SARS-COV-2 infections can be asymptomatic or cause only mild symptoms.IMPORTANCE The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has caused vast morbidity and mortality worldwide, yet several studies indicate that there may be a significant number of infected people who are asymptomatic or exhibit mild symptoms. In this study, samples were collected from healthy blood donors in a region of rapidly increasing disease burden (New York metropolitan area) and we hypothesized that a subset would be seropositive to SARS-CoV-2. People who experienced mild or no symptoms during SARS-CoV-2 infection may represent a source for convalescent plasma donors.Competing Interest StatementSerimmune employees (K.K., E.B.J., G.J., W.H., R.W., J.S., S.K., P.D.) receive salary and stock options from Serimmune.Funding StatementSARS-CoV-2 sample collection and curation by the Yale IMPACT team was supported by the Yale COVID-19 resource research fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Santa Barbara Cottage Hospital IRB and Yale IMPACT COVID-19 resource research IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from SERA assay is not available.